Outright purchase of a manufacturing Pharma unit having Global presence, “early stage project” - Formulation Pharma Plant (Maharashtra, India)

By Sandeep-Maniyar-1470
Posted On: 21 / Oct / 2022
1 550

Deal Details

Annual

Deal Type

Sell (Strategic Investors)
Maximum Loan

Industry

Pharmaceuticals
Charge

Deal Status

Active

Deal Description

Reason for Unit currently operating at 8% capacity and negative bottom line and cash flows

ØPlant was installed in March 2018 & commercial production license Dec 2018

ØRevenue operations commenced only in June – 2019

ØOnly 2 early years of Revenue curve & hence the above INR 40 million topline (8% of potential)

Ø

Other significant current considerations

ØPlant has been classified NPA for more than 1 year as Company unable to repay – Term + Covid loan of INR 110 Mln & further INR 34 Mln CC given the negative cash flows currently

Attached Files

icon Pharma Profile (1) pptx

Login To Download
Deal Value
₹ 35 Crore
Targeted Region
Asia Pacific

Revenue

2019-20
₹ 2.1 Crore
2020-21
₹ 4.2 Crore
2021-22
Undisclosed
Add to wishlist

You May Also Like